Literature DB >> 18758972

Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility.

Eduardo Nagore1, Carolina Pereda, Rafael Botella-Estrada, Celia Requena, Carlos Guillén.   

Abstract

BACKGROUND: Acral lentiginous melanoma (ALM) is a distinct histological variant of cutaneous melanoma that presents a genomic profile different from the other variants. Our aim was to explore the distinctive clinical, pathological, and epidemiological characteristics of ALM. PATIENTS AND METHODS: A series of 978 patients with primary cutaneous melanoma was selected from a single referral center. Among these, 79 were located on acral sites and 46 presented an ALM. This group was compared with a group composed of 932 patients with the remaining three most frequent cutaneous melanoma variants.
RESULTS: The ALM differed significantly from other variants: in an older age at diagnosis (65.52 vs. 51.79 years), a lower number of common (88.2 vs. 55.8%) and atypical nevi (95.0 vs. 80.2%), a predisposing genetic trait to cancer (22.2 vs. 7.1% had a personal history of other non-cutaneous malignancies and 58.1 vs. 36.4% had at least one first degree relative with non-cutaneous neoplasia) and lower number of sunburns (88.2 vs. 47.4% remembered none). Also, the tumors were thicker (mean of 2.94 vs. 2.03 mm), more frequently ulcerated (74.2 vs. 23.9%) and with perineural invasion (8.0 vs. 1.5%), had lower degree of inflammatory infiltrate (36.8 vs. 7.5% was absent) and were less frequently associated with a previous melanocytic lesion (8.3 vs. 32.6%). Differences were kept even after age-adjusted analyses.
CONCLUSIONS: Our results, from a clinical and epidemiological point of view, support recent data on genetic characterization of melanomas. In comparison with the other frequent variants we have shown that ALM has some important differences which emphasize that it is a distinct entity more probably related to certain cancer susceptibility but unrelated to familial melanoma, tendency to developing nevus or sun exposure.

Entities:  

Mesh:

Year:  2008        PMID: 18758972     DOI: 10.1007/s10552-008-9221-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  10 in total

Review 1.  Is UV an etiological factor of acral melanoma?

Authors:  Lin Liu; Weigang Zhang; Tianwen Gao; Chunying Li
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-10-14       Impact factor: 5.563

2.  Clinical and genetic analysis of melanomas arising in acral sites.

Authors:  Anne Zaremba; Rajmohan Murali; Philipp Jansen; Inga Möller; Antje Sucker; Annette Paschen; Lisa Zimmer; Elisabeth Livingstone; Titus J Brinker; Eva Hadaschik; Cindy Franklin; Alexander Roesch; Selma Ugurel; Dirk Schadendorf; Klaus G Griewank; Ioana Cosgarea
Journal:  Eur J Cancer       Date:  2019-08-14       Impact factor: 9.162

3.  Characterization of nonacral melanoma patients without typical risk factors.

Authors:  Maria M Canelas; Justo Lorenzo Bermejo; Maria Teresa Landi; Celia Requena; Carlos Guillen; Rajiv Kumar; Eduardo Nagore
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

4.  Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?

Authors:  Patrick Scanlon; Jaiying Tian; Judy Zhong; Ines Silva; Richard Shapiro; Anna Pavlick; Russell Berman; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2014-04-18       Impact factor: 3.466

5.  Whole genome sequencing of matched primary and metastatic acral melanomas.

Authors:  Samra Turajlic; Simon J Furney; Maryou B Lambros; Costas Mitsopoulos; Iwanka Kozarewa; Felipe C Geyer; Alan Mackay; Jarle Hakas; Marketa Zvelebil; Christopher J Lord; Alan Ashworth; Meirion Thomas; Gordon Stamp; James Larkin; Jorge S Reis-Filho; Richard Marais
Journal:  Genome Res       Date:  2011-12-19       Impact factor: 9.043

6.  [Thick cutaneous melanoma: mortality factors and occurrence of metastases].

Authors:  Mariam Tarwate; Hakima Benchikhi; Latifa Adarmouch; Abdelatif Benider; Mohamed Amine; Soumya Zamiati; El Hassan Boukind
Journal:  Pan Afr Med J       Date:  2014-05-12

7.  The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma.

Authors:  Xiaoting Wei; Di Wu; Hang Li; Rui Zhang; Yu Chen; Hong Yao; Zhihong Chi; Xinan Sheng; Chuanliang Cui; Xue Bai; Zhonghui Qi; Ke Li; Shijie Lan; Lizhu Chen; Rui Guo; Xinyu Yao; Lili Mao; Bin Lian; Yan Kong; Jie Dai; Bixia Tang; Xieqiao Yan; Xuan Wang; Siming Li; Li Zhou; Charles M Balch; Lu Si; Jun Guo
Journal:  Ann Surg Oncol       Date:  2020-04-06       Impact factor: 5.344

Review 8.  Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.

Authors:  Patricia Basurto-Lozada; Christian Molina-Aguilar; Carolina Castaneda-Garcia; Martha Estefania Vázquez-Cruz; Omar Isaac Garcia-Salinas; Alethia Álvarez-Cano; Héctor Martínez-Said; Rodrigo Roldán-Marín; David J Adams; Patricia A Possik; Carla Daniela Robles-Espinoza
Journal:  Pigment Cell Melanoma Res       Date:  2020-06-17       Impact factor: 4.693

9.  MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project.

Authors:  Saverio Caini; Sara Gandini; Francesca Botta; Elena Tagliabue; Sara Raimondi; Eduardo Nagore; Ines Zanna; Patrick Maisonneuve; Julia Newton-Bishop; David Polsky; DeAnn Lazovich; Rajiv Kumar; Peter A Kanetsky; Veronica Hoiom; Paola Ghiorzo; Maria Teresa Landi; Gloria Ribas; Chiara Menin; Alexander J Stratigos; Giuseppe Palmieri; Gabriella Guida; Jose Carlos García-Borrón; Hongmei Nan; Julian Little; Francesco Sera; Susana Puig; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2020-10       Impact factor: 3.199

Review 10.  Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox.

Authors:  Alina Goldenberg; Igor Vujic; Martina Sanlorenzo; Susana Ortiz-Urda
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.